BLAINJECTIONINJECTABLEPriority Review
Approved
Mar 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
62
Data completeness
6/8 — Strong
Priority Review
OCREVUS (ocrelizumab) by Roche is cd20-directed antibody interactions [moa]. Approved for multiple sclerosis, relapsing-remitting, primary progressive multiple sclerosis. First approved in 2017.
Drug data last refreshed 6d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OCREVUS (ocrelizumab) is a CD20-directed cytolytic monoclonal antibody approved by the FDA on March 28, 2017, developed by Roche. It is indicated for the treatment of multiple sclerosis by targeting CD20+ B cells to reduce inflammation and disease progression. The drug represents a key therapeutic option in the MS market, offering both relapsing and progressive forms of the disease management through B-cell depletion mechanism.
$0.2BPart D
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Worked on OCREVUS at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.